Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation

Muhammad Mujtaba, W. J. Komocsar, E. Nantz, M. D. Samaniego, S. L. Henson, J. A. Hague, A. L. Lobashevsky, N. G. Higgins, M. Czader, B. K. Book, M. D. Anderson, M. D. Pescovitz, T. E. Taber

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

B cell-activation factor (BAFF) is critical for B cell maturation. Inhibition of BAFF represents an appealing target for desensitization of sensitized end-stage renal disease (ESRD) patients. We conducted a Phase 2a, single-arm, open-label exploratory study investigating the effect of tabalumab (BAFF inhibitor) in patients with ESRD and calculated panel reactive antibodies (cPRAs) >50%. The treatment period duration was 24 weeks. Eighteen patients received tabalumab, at doses of 240-mg subcutaneous (SC) at Week 0 followed by 120-mg SC monthly for 5 additional months. Patients were followed for an additional 52 weeks. Immunopharmacologic effects were characterized through analysis of blood for HLA antibodies, BAFF concentrations, immunoglobulins, T and B cell subsets, as well as pre- and posttreatment tonsil and bone marrow biopsies. Significant reductions in cPRAs were observed at Weeks 16 (p=0.043) and 36 (p=0.004); however, absolute reductions were small (

Original languageEnglish (US)
JournalAmerican Journal of Transplantation
DOIs
StateAccepted/In press - 2016

Fingerprint

B-Cell Activating Factor
Chronic Kidney Failure
Transplantation
Antibodies
B-Lymphocytes
B-Lymphocyte Subsets
Palatine Tonsil
T-Lymphocyte Subsets
Therapeutics
Bone Marrow
Biopsy
tabalumab

Keywords

  • Alloantibody
  • B cell biology
  • Basic (laboratory) research/science
  • Clinical research/practice
  • Desensitization
  • Fusion proteins and monoclonal antibodies: B cell specific
  • Immunobiology
  • Immunosuppressant
  • Kidney transplantation/nephrology

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation. / Mujtaba, Muhammad; Komocsar, W. J.; Nantz, E.; Samaniego, M. D.; Henson, S. L.; Hague, J. A.; Lobashevsky, A. L.; Higgins, N. G.; Czader, M.; Book, B. K.; Anderson, M. D.; Pescovitz, M. D.; Taber, T. E.

In: American Journal of Transplantation, 2016.

Research output: Contribution to journalArticle

Mujtaba, M, Komocsar, WJ, Nantz, E, Samaniego, MD, Henson, SL, Hague, JA, Lobashevsky, AL, Higgins, NG, Czader, M, Book, BK, Anderson, MD, Pescovitz, MD & Taber, TE 2016, 'Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation', American Journal of Transplantation. https://doi.org/10.1111/ajt.13557
Mujtaba, Muhammad ; Komocsar, W. J. ; Nantz, E. ; Samaniego, M. D. ; Henson, S. L. ; Hague, J. A. ; Lobashevsky, A. L. ; Higgins, N. G. ; Czader, M. ; Book, B. K. ; Anderson, M. D. ; Pescovitz, M. D. ; Taber, T. E. / Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation. In: American Journal of Transplantation. 2016.
@article{c29aa6dfc6d24266af81c769113f95e7,
title = "Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation",
abstract = "B cell-activation factor (BAFF) is critical for B cell maturation. Inhibition of BAFF represents an appealing target for desensitization of sensitized end-stage renal disease (ESRD) patients. We conducted a Phase 2a, single-arm, open-label exploratory study investigating the effect of tabalumab (BAFF inhibitor) in patients with ESRD and calculated panel reactive antibodies (cPRAs) >50{\%}. The treatment period duration was 24 weeks. Eighteen patients received tabalumab, at doses of 240-mg subcutaneous (SC) at Week 0 followed by 120-mg SC monthly for 5 additional months. Patients were followed for an additional 52 weeks. Immunopharmacologic effects were characterized through analysis of blood for HLA antibodies, BAFF concentrations, immunoglobulins, T and B cell subsets, as well as pre- and posttreatment tonsil and bone marrow biopsies. Significant reductions in cPRAs were observed at Weeks 16 (p=0.043) and 36 (p=0.004); however, absolute reductions were small (",
keywords = "Alloantibody, B cell biology, Basic (laboratory) research/science, Clinical research/practice, Desensitization, Fusion proteins and monoclonal antibodies: B cell specific, Immunobiology, Immunosuppressant, Kidney transplantation/nephrology",
author = "Muhammad Mujtaba and Komocsar, {W. J.} and E. Nantz and Samaniego, {M. D.} and Henson, {S. L.} and Hague, {J. A.} and Lobashevsky, {A. L.} and Higgins, {N. G.} and M. Czader and Book, {B. K.} and Anderson, {M. D.} and Pescovitz, {M. D.} and Taber, {T. E.}",
year = "2016",
doi = "10.1111/ajt.13557",
language = "English (US)",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation

AU - Mujtaba, Muhammad

AU - Komocsar, W. J.

AU - Nantz, E.

AU - Samaniego, M. D.

AU - Henson, S. L.

AU - Hague, J. A.

AU - Lobashevsky, A. L.

AU - Higgins, N. G.

AU - Czader, M.

AU - Book, B. K.

AU - Anderson, M. D.

AU - Pescovitz, M. D.

AU - Taber, T. E.

PY - 2016

Y1 - 2016

N2 - B cell-activation factor (BAFF) is critical for B cell maturation. Inhibition of BAFF represents an appealing target for desensitization of sensitized end-stage renal disease (ESRD) patients. We conducted a Phase 2a, single-arm, open-label exploratory study investigating the effect of tabalumab (BAFF inhibitor) in patients with ESRD and calculated panel reactive antibodies (cPRAs) >50%. The treatment period duration was 24 weeks. Eighteen patients received tabalumab, at doses of 240-mg subcutaneous (SC) at Week 0 followed by 120-mg SC monthly for 5 additional months. Patients were followed for an additional 52 weeks. Immunopharmacologic effects were characterized through analysis of blood for HLA antibodies, BAFF concentrations, immunoglobulins, T and B cell subsets, as well as pre- and posttreatment tonsil and bone marrow biopsies. Significant reductions in cPRAs were observed at Weeks 16 (p=0.043) and 36 (p=0.004); however, absolute reductions were small (

AB - B cell-activation factor (BAFF) is critical for B cell maturation. Inhibition of BAFF represents an appealing target for desensitization of sensitized end-stage renal disease (ESRD) patients. We conducted a Phase 2a, single-arm, open-label exploratory study investigating the effect of tabalumab (BAFF inhibitor) in patients with ESRD and calculated panel reactive antibodies (cPRAs) >50%. The treatment period duration was 24 weeks. Eighteen patients received tabalumab, at doses of 240-mg subcutaneous (SC) at Week 0 followed by 120-mg SC monthly for 5 additional months. Patients were followed for an additional 52 weeks. Immunopharmacologic effects were characterized through analysis of blood for HLA antibodies, BAFF concentrations, immunoglobulins, T and B cell subsets, as well as pre- and posttreatment tonsil and bone marrow biopsies. Significant reductions in cPRAs were observed at Weeks 16 (p=0.043) and 36 (p=0.004); however, absolute reductions were small (

KW - Alloantibody

KW - B cell biology

KW - Basic (laboratory) research/science

KW - Clinical research/practice

KW - Desensitization

KW - Fusion proteins and monoclonal antibodies: B cell specific

KW - Immunobiology

KW - Immunosuppressant

KW - Kidney transplantation/nephrology

UR - http://www.scopus.com/inward/record.url?scp=84955092858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955092858&partnerID=8YFLogxK

U2 - 10.1111/ajt.13557

DO - 10.1111/ajt.13557

M3 - Article

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

ER -